Lupin secures a place in S&P Global Sustainability Yearbook 2025
Yearbook members are selected basis their S&P Global 2024 Corporate Sustainability Assessment score
Yearbook members are selected basis their S&P Global 2024 Corporate Sustainability Assessment score
VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives
This launch of Epinephrine Injection multiple-dose Vial is eligible for 180 days of CGT exclusivity under section 505(j)(5)(B)(v) of the FD&C Act.
The observations issued are neither repeated observations nor related to data integrity
Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
Subscribe To Our Newsletter & Stay Updated